- Home
- ANL vs SER Comparison
ANL vs SER Comparison
Compare ANL & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- SER
- Stock Information
- Founded
- ANL 2004
- SER 2017
- Country
- ANL Cayman Islands
- SER United States
- Employees
- ANL N/A
- SER N/A
- Industry
- ANL
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- SER Health Care
- Exchange
- ANL Nasdaq
- SER Nasdaq
- Market Cap
- ANL 61.8M
- SER 55.2M
- IPO Year
- ANL 2023
- SER 2018
- Fundamental
- Price
- ANL $1.79
- SER $5.39
- Analyst Decision
- ANL Hold
- SER Strong Buy
- Analyst Count
- ANL 1
- SER 2
- Target Price
- ANL N/A
- SER $13.00
- AVG Volume (30 Days)
- ANL 11.3K
- SER 24.9K
- Earning Date
- ANL 10-21-2025
- SER 11-11-2025
- Dividend Yield
- ANL N/A
- SER N/A
- EPS Growth
- ANL N/A
- SER N/A
- EPS
- ANL N/A
- SER N/A
- Revenue
- ANL N/A
- SER $130,000.00
- Revenue This Year
- ANL N/A
- SER $17.23
- Revenue Next Year
- ANL N/A
- SER N/A
- P/E Ratio
- ANL N/A
- SER N/A
- Revenue Growth
- ANL N/A
- SER N/A
- 52 Week Low
- ANL $1.10
- SER $3.81
- 52 Week High
- ANL $3.89
- SER $8.14
- Technical
- Relative Strength Index (RSI)
- ANL 55.55
- SER 55.25
- Support Level
- ANL $1.70
- SER $5.09
- Resistance Level
- ANL $1.82
- SER $5.49
- Average True Range (ATR)
- ANL 0.09
- SER 0.25
- MACD
- ANL -0.00
- SER 0.05
- Stochastic Oscillator
- ANL 60.33
- SER 83.84
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.